Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefanie S Schalm

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Current Biology : CB|April 23, 2002
Identification of a conserved motif required for mTOR signalingStefanie S Schalm, John Blenis
Seminars in Cell & Developmental Biology|June 24, 2004
PI3-kinase and TOR: PIKTORing cell growthCeleste J Richardson, Stefanie S Schalm, John Blenis
The Journal of Biological Chemistry|January 22, 2005
Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulationStefanie S Schalm, Andrew R Tee, John Blenis
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2010
Proteolytic processing of protocadherin proteins requires endocytosisSean M Buchanan, Stefanie S Schalm, Tom Maniatis
Current Biology : CB|May 16, 2003
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and functionStefanie S Schalm, Diane C Fingar, David M Sabatini, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Phosphorylation of protocadherin proteins by the receptor tyrosine kinase RetStefanie S Schalm, Bryan A Ballif, Sean M Buchanan, et al.
Gastro Hep Advances|August 12, 2024
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar CarcinomaStefanie S Schalm, Erin O'Hearn, Kevin Wilson, et al.
Therapeutic Advances in Medical Oncology|October 24, 2024
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancerSun Min Lim, Stefanie S Schalm, Eun Ji Lee, et al.
Molecular Cancer Therapeutics|December 9, 2024
KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule InhibitorsYogesh K Chutake, Michele F Mayo, Nancy Dumont, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Current Biology : CB|April 23, 2002
Identification of a conserved motif required for mTOR signalingStefanie S Schalm, John Blenis
Seminars in Cell & Developmental Biology|June 24, 2004
PI3-kinase and TOR: PIKTORing cell growthCeleste J Richardson, Stefanie S Schalm, John Blenis
The Journal of Biological Chemistry|January 22, 2005
Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulationStefanie S Schalm, Andrew R Tee, John Blenis
Proceedings of the National Academy of Sciences of the United States of America|September 30, 2010
Proteolytic processing of protocadherin proteins requires endocytosisSean M Buchanan, Stefanie S Schalm, Tom Maniatis
Current Biology : CB|May 16, 2003
TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and functionStefanie S Schalm, Diane C Fingar, David M Sabatini, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 10, 2010
Phosphorylation of protocadherin proteins by the receptor tyrosine kinase RetStefanie S Schalm, Bryan A Ballif, Sean M Buchanan, et al.
Gastro Hep Advances|August 12, 2024
Evaluation of Protein Kinase cAMP-Activated Catalytic Subunit Alpha as a Therapeutic Target for Fibrolamellar CarcinomaStefanie S Schalm, Erin O'Hearn, Kevin Wilson, et al.
Therapeutic Advances in Medical Oncology|October 24, 2024
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancerSun Min Lim, Stefanie S Schalm, Eun Ji Lee, et al.
Molecular Cancer Therapeutics|December 9, 2024
KT-253, a Novel MDM2 Degrader and p53 Stabilizer, Has Superior Potency and Efficacy than MDM2 Small-Molecule InhibitorsYogesh K Chutake, Michele F Mayo, Nancy Dumont, et al.
Pageof 1